Skip to main content

Defendants’ Talc Suit Summary Judgment Motion Denied

Defendants’ Talc Suit Summary Judgment Motion Denied

Defendants’ Talc Suit Summary Judgment Motion Denied

Introduction

In an order submitted on December 10, the New York Supreme Court rejected Colgate-Palmolive's motion for summary judgment in a Cashmere Bouquet talcum powder lawsuit with the conclusion that the issue still remained whether the plaintiff's use of the talcum powder led to her mesothelioma. The order stated summary judgment could not be granted “when there is any doubt” on causation.

The plaintiff claimed in her lawsuit that she developed mesothelioma as she was in contact with Colgate-Palmolive Co.’s cosmetic talc product from 1968 through 1985. She filed suit against Imerys Talc America, Inc. and Cyprus Amax Minerals Companies blaming them for her illness. In their motion for summary judgment, the defendants, Imerys and Cyprus asserted that they both are Delaware corporations and were not involved in mining, manufacturing, research, development, designing, or testing of the talcum powder in the state hence, they cannot be held liable in New York for the damages caused to the plaintiff. The Supreme Court denied their motion considering that both companies actively sold and shipped talc to Colgate-Palmolive in New York for nearly six years hence the case must proceed to trial.

Mesothelioma affected plaintiffs have filed asbestos exposure lawsuits in several state and county courts. Individuals working in factories and mines where asbestos products are used often fall prey to the deadly form of cancer.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!